Pfizer has announced a global strategic collaboration with France-based Cellectis for development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.

Cellectis claims that its CAR-T technology provides an allogeneic approach to developing CAR-T therapies that is distinct from other autologous approaches.

Under the terms, Pfizer will have exclusive rights to develop and commercialise CAR-T therapies in the field of oncology, directed at a total of 15 targets selected by the company.

Pfizer and Cellectis will work together on preclinical research, with Pfizer responsible for development and potential commercialisation of any CAR-T therapies for company-selected targets.

"Pfizer will have exclusive rights to develop and commercialise CAR-T therapies in the field of oncology."

In addition, the agreement provides for a total of 12 targets selected by Cellectis. Both companies will work together on preclinical research on four Cellectis-selected targets, while Cellectis will work independently on eight additional targets.

Cellectis will be responsible for clinical development and commercialisation of CAR-T therapeutics for company-selected targets.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Under the deal, Pfizer will pay an upfront payment of $80m to Cellectis, as well as funding for research and development costs associated with Pfizer-selected targets and the four Cellectis-selected targets within the collaboration.

Cellectis will also be eligible to get development, regulatory and commercial milestone payments of up to $185m per Pfizer product, plus tiered royalties on any eventual sales.

In addition, Pfizer will also buy a stake of 10% in Cellectis through newly issued shares at €9.25 per share, pending Cellectis shareholder approval. Pfizer has the option to terminate the collaboration agreement if the sale of equity is not approved by the Cellectis shareholders.

Pfizer R&D president Dr Mikael Dolsten said: "Combining the innovation and scientific expertise of Cellectis with Pfizer’s deep oncology and immunology experience creates a world-class partnership designed to deliver a new generation of CAR-T immunotherapies for cancer patients with urgent medical needs."

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now